SG11201901558VA - Pth compounds with low peak-to-trough ratios - Google Patents
Pth compounds with low peak-to-trough ratiosInfo
- Publication number
- SG11201901558VA SG11201901558VA SG11201901558VA SG11201901558VA SG11201901558VA SG 11201901558V A SG11201901558V A SG 11201901558VA SG 11201901558V A SG11201901558V A SG 11201901558VA SG 11201901558V A SG11201901558V A SG 11201901558VA SG 11201901558V A SG11201901558V A SG 11201901558VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- pth
- english
- september
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Reverberation, Karaoke And Other Acoustics (AREA)
- Bipolar Transistors (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16191454 | 2016-09-29 | ||
EP17155846 | 2017-02-13 | ||
PCT/EP2017/074594 WO2018060312A1 (en) | 2016-09-29 | 2017-09-28 | Pth compounds with low peak-to-trough ratios |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201901558VA true SG11201901558VA (en) | 2019-03-28 |
Family
ID=60051489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901558VA SG11201901558VA (en) | 2016-09-29 | 2017-09-28 | Pth compounds with low peak-to-trough ratios |
Country Status (25)
Country | Link |
---|---|
US (4) | US11759504B2 (da) |
EP (2) | EP4218795A3 (da) |
JP (2) | JP7085535B2 (da) |
KR (2) | KR20230170810A (da) |
CN (2) | CN109789188B (da) |
AU (1) | AU2017336251B2 (da) |
BR (1) | BR112019005793A2 (da) |
CA (1) | CA3037447A1 (da) |
DK (1) | DK3518961T3 (da) |
ES (1) | ES2943720T3 (da) |
FI (1) | FI3518961T3 (da) |
HR (1) | HRP20230383T1 (da) |
HU (1) | HUE062009T2 (da) |
IL (1) | IL265601A (da) |
LT (1) | LT3518961T (da) |
MA (1) | MA46345A (da) |
MX (1) | MX2019003182A (da) |
NZ (1) | NZ751745A (da) |
PL (1) | PL3518961T3 (da) |
RS (1) | RS64177B1 (da) |
RU (1) | RU2766959C2 (da) |
SG (1) | SG11201901558VA (da) |
SI (1) | SI3518961T1 (da) |
WO (1) | WO2018060312A1 (da) |
ZA (1) | ZA201901813B (da) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3220961B1 (en) | 2014-10-22 | 2023-07-05 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
RU2747316C2 (ru) * | 2016-03-01 | 2021-05-04 | Асцендис Фарма Боун Дизизис А/С | Пролекарства pth |
ES2959995T3 (es) * | 2016-09-29 | 2024-02-29 | Ascendis Pharma Bone Diseases As | Pauta de dosificación para un compuesto de pth de liberación controlada |
RS64177B1 (sr) | 2016-09-29 | 2023-05-31 | Ascendis Pharma Bone Diseases As | Jedinjenja pth sa niskim odnosima najviše i najniže koncentracije |
US11975050B2 (en) * | 2018-03-16 | 2024-05-07 | The General Hospital Corporation | Parathyroid hormone polypeptide conjugates and methods of their use |
CN113423383A (zh) | 2019-02-11 | 2021-09-21 | 阿森迪斯药物骨疾病股份有限公司 | Pth缀合物的液体药物制剂 |
JP2023510790A (ja) | 2020-01-13 | 2023-03-15 | アセンディス ファーマ ボーン ディジージズ エー/エス | 副甲状腺機能低下症の治療 |
CA3192772A1 (en) | 2020-09-28 | 2022-03-31 | Ascendis Pharma Bone Diseases A/S | Improvement of physical and mental well-being of patients with hypoparathyroidism |
AU2022350937A1 (en) | 2021-09-22 | 2024-03-21 | Ascendis Pharma Bone Diseases A/S | Long-acting pth compound treatments |
WO2024094673A1 (en) * | 2022-11-02 | 2024-05-10 | Ascendis Pharma Bone Diseases A/S | Pth treatment regimen comprising two pth compounds |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744444A (en) | 1989-10-27 | 1998-04-28 | Haemopep Pharma Gmbh | HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof |
US5567439A (en) | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
MY120063A (en) | 1997-12-09 | 2005-08-30 | Lilly Co Eli | Stabilized teriparatide solutions |
US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
US20050124537A1 (en) | 2000-04-27 | 2005-06-09 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
WO2003064462A1 (fr) | 2002-02-01 | 2003-08-07 | Chugai Seiyaku Kabushiki Kaisha | Pth a liaison peg ou derive de pth a liaison peg |
US6559293B1 (en) | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
JP4698579B2 (ja) | 2003-04-08 | 2011-06-08 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 可逆的peg化薬物 |
US7690003B2 (en) | 2003-08-29 | 2010-03-30 | Fuller Jeffrey C | System and method for increasing data throughput using thread scheduling |
US20070203058A1 (en) | 2003-09-19 | 2007-08-30 | Novo Nordisk A/S | Novel Glp-1 Derivatives |
DK1732607T3 (da) | 2004-03-23 | 2019-07-22 | Ascendis Pharma Gmbh | Polymer-prodrug med en selvofrende linker |
CA2567056A1 (en) | 2004-05-10 | 2005-12-08 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
CN1597697A (zh) | 2004-07-19 | 2005-03-23 | 中国药科大学 | 一种人的甲状旁腺素1-34肽相关肽-Pro-Pro-[Arg11]]hPTH(1-34)-Pro-Pro |
US20060069021A1 (en) * | 2004-08-13 | 2006-03-30 | Nastech Pharmaceutical Company Inc. | Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs |
CA2582255A1 (en) | 2004-08-30 | 2006-08-08 | Lunamed, Inc. | 4-phenylbutyric acid controlled-release formulations for therapeutic use |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
CN1298386C (zh) | 2005-08-31 | 2007-02-07 | 上海交通大学 | 甲状旁腺激素缓释微球的制备方法 |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
JP2009530307A (ja) | 2006-03-15 | 2009-08-27 | アルザ コーポレイション | 骨減少症を予防し、または治療するための副甲状腺ホルモン薬の経皮送達のための装置、並びに方法 |
AU2007296054B2 (en) | 2006-09-15 | 2013-03-28 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
KR101108354B1 (ko) * | 2006-10-13 | 2012-01-25 | 일라이 릴리 앤드 캄파니 | Pth 수용체 조절제로서의 페길화된 pth 및 그의 용도 |
US8101729B2 (en) | 2007-03-19 | 2012-01-24 | Henry Joseph Niemczyk | Pegylated amino acid derivatives and the process to synthesize the same |
CA2683862C (en) | 2007-04-09 | 2016-08-02 | The Board Of Trustees Of The University Of Arkansas | Fusion protein of collagen-binding domain and parathyroid hormone |
CN101063125A (zh) | 2007-04-17 | 2007-10-31 | 江南大学 | 人甲状旁腺激素与人血清白蛋白的融合蛋白的制备方法及产品 |
SI2173890T1 (sl) | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
TW200922624A (en) | 2007-07-11 | 2009-06-01 | Enzon Pharmaceuticals Inc | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
EP2052736A1 (en) | 2007-10-26 | 2009-04-29 | Nycomed Danmark ApS | Parathyroid hormone formulations und uses thereof |
HUE044174T2 (hu) | 2008-02-01 | 2019-10-28 | Ascendis Pharma As | Önhasítható linkert tartalmazó elõvegyület |
MX2010011800A (es) | 2008-04-29 | 2011-06-20 | Ascendis Pharma As | Compuestos de hormona de crecimiento humana recombinante unidos a peg. |
EP2288261A4 (en) | 2008-05-23 | 2013-09-25 | Enzon Pharmaceuticals Inc | POLYMER SYSTEMS CONTAINING INTRA-CELLULAR RELEASE DISULFID LINKERS FOR THE DISPOSAL OF OLIGONUCLEOTIDES |
WO2009156481A1 (en) | 2008-06-25 | 2009-12-30 | Ascendis Pharma As | Pegylated bnp |
EP2331112A1 (en) | 2008-08-19 | 2011-06-15 | Ferring B.V. | Peptidic pth receptor agonists |
MX362028B (es) | 2009-02-03 | 2019-01-04 | Amunix Pharmaceuticals Inc | Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos. |
EP2459227B1 (en) | 2009-07-31 | 2021-03-17 | Ascendis Pharma A/S | Prodrugs containing an aromatic amine connected by an amide bond to a carrier |
MA33466B1 (fr) * | 2009-07-31 | 2012-07-03 | Sanofi Aventis Deutschland | Composition d'insuline à longue duree d'action |
KR101770844B1 (ko) | 2009-07-31 | 2017-08-23 | 아센디스 파마 에이에스 | 폴리에틸렌 글리콜 기반의 생분해성 수불용성 하이드로겔 |
WO2011012723A1 (en) * | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Injectable sustained release compositions comprising a pramipexole prodrug |
WO2011012721A1 (en) * | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Carrier linked pramipexole prodrugs |
MX2012001399A (es) | 2009-07-31 | 2012-03-21 | Sanofi Aventis Deutschland | Profarmacos que comprenden un conjugado de insulina-conector. |
ITMI20091512A1 (it) | 2009-08-28 | 2011-02-28 | Al Ma C Packaging S R L | Procedimento per il confezionamento di gruppi di contenitori per prodotti liquidi alimentari, in particolare bottiglie di acqua e/o bevande, e fardello ottenibile per mezzo di tale procedimento |
US20130053405A1 (en) * | 2009-10-06 | 2013-02-28 | Ulrich Hersel | Carrier linked paliperidone prodrugs |
JP2013513647A (ja) | 2009-12-15 | 2013-04-22 | アセンディス ファーマ エー/エス | ポリマー担体に一時的に連結された乾燥成長ホルモン組成物 |
US20120289571A1 (en) | 2009-12-31 | 2012-11-15 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of aromatic amine containing compounds including releasable urea linker |
US9561285B2 (en) * | 2010-01-22 | 2017-02-07 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
US9062094B2 (en) | 2010-01-22 | 2015-06-23 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
US20130030359A1 (en) | 2010-01-22 | 2013-01-31 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
US20110229580A1 (en) | 2010-03-22 | 2011-09-22 | Indian Institute of Technology Bombay, School of Biosciences and Bioengineering | Compositions and methods for nano-in-micro particles |
EP3372617B1 (en) | 2010-04-02 | 2024-07-24 | Amunix Pharmaceuticals, Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
ES2584381T3 (es) | 2010-05-05 | 2016-09-27 | Prolynx Llc | Liberación controlada de compuestos activos desde conjugados macromoleculares |
JP5964815B2 (ja) | 2010-05-05 | 2016-08-03 | プロリンクス リミテッド ライアビリティ カンパニー | 固体担体からの放出制御薬物 |
MX358161B (es) | 2010-05-13 | 2018-08-06 | The General Hospital Corp Star | Analogos de hormona paratiroidea y usos para los mismos. |
WO2011144756A1 (en) | 2010-05-21 | 2011-11-24 | Xl-Protein Gmbh | Biosynthetic proline/alanine random coil polypeptides and their uses |
US8865220B2 (en) * | 2010-06-14 | 2014-10-21 | Kaohsiung Medical University | Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres |
WO2012002047A1 (ja) | 2010-06-30 | 2012-01-05 | Necソフト株式会社 | 属性判定方法、属性判定装置、プログラム、記録媒体および属性判定システム |
US20120040320A1 (en) | 2010-08-13 | 2012-02-16 | Nadeau Daniel A | Injection Simulation Device and Methods Thereof |
EP2438930A1 (en) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
JP2014522878A (ja) * | 2011-08-12 | 2014-09-08 | アセンディス ファーマ エー/エス | プロスタサイクリンの徐放組成物 |
JP6092867B2 (ja) | 2011-08-12 | 2017-03-08 | アセンディス ファーマ エー/エス | 担体連結しているトレプロスチニルプロドラッグ |
EP2741744A1 (en) * | 2011-08-12 | 2014-06-18 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
CA2843503C (en) | 2011-08-12 | 2020-12-22 | Ulrich Hersel | Polymeric hyperbranched carrier-linked prodrugs |
US20140323402A1 (en) | 2011-08-12 | 2014-10-30 | Ascendis Phama A/S | Protein Carrier-Linked Prodrugs |
WO2013036857A1 (en) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
AU2012322917B2 (en) * | 2011-10-12 | 2016-11-03 | Ascendis Pharma Ophthalmology Division A/S | Prevention and treatment of ocular conditions |
US8883862B2 (en) | 2012-01-12 | 2014-11-11 | Kaohsiung Medical University | Method for controlled release of parathyroid hormone from cross-linked hyaluronic acid hydrogel |
CA2868925C (en) | 2012-04-25 | 2020-01-21 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
US9457096B2 (en) | 2012-07-06 | 2016-10-04 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) | Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery |
CA2883707A1 (en) | 2012-08-28 | 2014-03-06 | The Governors Of The University Of Alberta | Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods of making and using thereof |
JP6271566B2 (ja) * | 2012-10-11 | 2018-01-31 | アセンディス ファーマ エー/エス | ヒドロゲルプロドラッグ |
RU2682676C2 (ru) | 2012-10-11 | 2019-03-20 | Асцендис Фарма Ас | Диагностика, профилактика и лечение болезней суставов |
SG11201501914XA (en) * | 2012-10-11 | 2015-05-28 | Ascendis Pharma Ophthalmology Division As | Vegf neutralizing prodrugs for the treatment of ocular conditions |
JP2015536314A (ja) | 2012-10-17 | 2015-12-21 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 成長ホルモン送達のための脂肪酸アシル化アミノ酸 |
EP2928501B1 (en) * | 2012-12-07 | 2020-05-06 | Ascendis Pharma A/S | Carrier-linked prostanoid prodrugs |
GB201303771D0 (en) | 2013-03-04 | 2013-04-17 | Midatech Ltd | Nanoparticles peptide compositions |
WO2014173759A1 (en) * | 2013-04-22 | 2014-10-30 | Ascendis Pharma A/S | Hydrogel-linked prodrugs releasing modified drugs |
WO2015031709A1 (en) | 2013-08-30 | 2015-03-05 | Perosphere, Inc. | Rapid acting injectable formulations comprising a peptide and a vasodilatory agent |
US10040850B2 (en) * | 2013-10-08 | 2018-08-07 | Ascendis Pharma A/S | Protecting group comprising a purification tag |
EP2868326A1 (en) | 2013-11-04 | 2015-05-06 | Université Pierre et Marie Curie (Paris 6) | Peptide inhibitors of TEAD/YAP-TAZ interaction |
EP3193941B1 (en) * | 2014-08-06 | 2024-05-22 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
EP3220961B1 (en) * | 2014-10-22 | 2023-07-05 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
EP3242689A1 (en) * | 2015-01-09 | 2017-11-15 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
RU2747316C2 (ru) | 2016-03-01 | 2021-05-04 | Асцендис Фарма Боун Дизизис А/С | Пролекарства pth |
DK3518930T3 (da) | 2016-09-29 | 2023-05-01 | Ascendis Pharma Growth Disorders As | Kombinationsbehandling af en CNP-agonist med kontrolleret frigivelse |
RS64177B1 (sr) | 2016-09-29 | 2023-05-31 | Ascendis Pharma Bone Diseases As | Jedinjenja pth sa niskim odnosima najviše i najniže koncentracije |
EP3518982A1 (en) | 2016-09-29 | 2019-08-07 | Ascendis Pharma Bone Diseases A/S | Incremental dose finding in controlled-release pth compounds |
ES2959995T3 (es) | 2016-09-29 | 2024-02-29 | Ascendis Pharma Bone Diseases As | Pauta de dosificación para un compuesto de pth de liberación controlada |
TW201832783A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 包含glp-1/胰高血糖素雙重激動劑、連接子和透明質酸的接合物 |
BR112020022306A2 (pt) | 2018-05-18 | 2021-02-23 | Ascendis Pharma Bone Diseases A/S | dose de partida de conjugados de pth |
CN113423383A (zh) | 2019-02-11 | 2021-09-21 | 阿森迪斯药物骨疾病股份有限公司 | Pth缀合物的液体药物制剂 |
JP2023510790A (ja) | 2020-01-13 | 2023-03-15 | アセンディス ファーマ ボーン ディジージズ エー/エス | 副甲状腺機能低下症の治療 |
-
2017
- 2017-09-28 RS RS20230344A patent/RS64177B1/sr unknown
- 2017-09-28 SI SI201731350T patent/SI3518961T1/sl unknown
- 2017-09-28 CA CA3037447A patent/CA3037447A1/en active Pending
- 2017-09-28 SG SG11201901558VA patent/SG11201901558VA/en unknown
- 2017-09-28 EP EP23157504.4A patent/EP4218795A3/en active Pending
- 2017-09-28 LT LTEPPCT/EP2017/074594T patent/LT3518961T/lt unknown
- 2017-09-28 RU RU2019112919A patent/RU2766959C2/ru active
- 2017-09-28 PL PL17781427.4T patent/PL3518961T3/pl unknown
- 2017-09-28 JP JP2019516692A patent/JP7085535B2/ja active Active
- 2017-09-28 EP EP17781427.4A patent/EP3518961B1/en active Active
- 2017-09-28 CN CN201780060139.7A patent/CN109789188B/zh active Active
- 2017-09-28 NZ NZ751745A patent/NZ751745A/en unknown
- 2017-09-28 US US16/337,955 patent/US11759504B2/en active Active
- 2017-09-28 DK DK17781427.4T patent/DK3518961T3/da active
- 2017-09-28 WO PCT/EP2017/074594 patent/WO2018060312A1/en unknown
- 2017-09-28 MX MX2019003182A patent/MX2019003182A/es unknown
- 2017-09-28 ES ES17781427T patent/ES2943720T3/es active Active
- 2017-09-28 HU HUE17781427A patent/HUE062009T2/hu unknown
- 2017-09-28 KR KR1020237041945A patent/KR20230170810A/ko active Application Filing
- 2017-09-28 FI FIEP17781427.4T patent/FI3518961T3/fi active
- 2017-09-28 MA MA046345A patent/MA46345A/fr unknown
- 2017-09-28 AU AU2017336251A patent/AU2017336251B2/en active Active
- 2017-09-28 HR HRP20230383TT patent/HRP20230383T1/hr unknown
- 2017-09-28 KR KR1020197012458A patent/KR102611820B1/ko active IP Right Grant
- 2017-09-28 CN CN202311052760.2A patent/CN117257922A/zh active Pending
- 2017-09-28 BR BR112019005793A patent/BR112019005793A2/pt unknown
-
2019
- 2019-03-25 IL IL265601A patent/IL265601A/en unknown
- 2019-03-25 ZA ZA2019/01813A patent/ZA201901813B/en unknown
-
2020
- 2020-08-10 US US16/989,225 patent/US20200360488A1/en not_active Abandoned
-
2022
- 2022-06-06 JP JP2022091286A patent/JP7434419B2/ja active Active
- 2022-11-08 US US18/053,701 patent/US11857603B2/en active Active
-
2023
- 2023-10-27 US US18/496,727 patent/US20240173385A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
SG11201909963YA (en) | Methods for treating dravet syndrome | |
SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
SG11201808686VA (en) | Synthesis of indazoles | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201901576QA (en) | Dosage regimen for a controlled-release pth compound | |
SG11201909807TA (en) | Methods of manufacturing of niraparib | |
SG11201804587QA (en) | Isoindole compounds | |
SG11201902949PA (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11202000494UA (en) | Drug delivery composition | |
SG11201908660RA (en) | N-substituted indole derivatives | |
SG11201906767XA (en) | Estrogen receptor modulators | |
SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction | |
SG11201907217RA (en) | Pharmaceutical combinations for treating cancer |